| Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ... Journal of clinical oncology 32 (13), 1302-1308, 2014 | 1707 | 2014 |
| Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I Melakopoulos, ... Journal of clinical Oncology 23 (34), 8580-8587, 2005 | 1609 | 2005 |
| Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 … T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ... The Lancet 391 (10122), 748-757, 2018 | 1385 | 2018 |
| Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial MD Galsky, JÁA Arija, A Bamias, ID Davis, M De Santis, E Kikuchi, ... The Lancet 395 (10236), 1547-1557, 2020 | 682 | 2020 |
| Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer R de Wit, J de Bono, CN Sternberg, K Fizazi, B Tombal, C Wülfing, ... New England Journal of Medicine 381 (26), 2506-2518, 2019 | 591 | 2019 |
| Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid MA Dimopoulos, E Kastritis, C Bamia, I Melakopoulos, D Gika, M Roussou, ... Annals of Oncology 20 (1), 117-120, 2009 | 577 | 2009 |
| Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma DF Bajorin, JA Witjes, JE Gschwend, M Schenker, BP Valderrama, ... New England Journal of Medicine 384 (22), 2102-2114, 2021 | 572 | 2021 |
| Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium DYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee, JJ Knox, ... European urology 66 (4), 704-710, 2014 | 505 | 2014 |
| Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid MA Dimopoulos, E Kastritis, A Anagnostopoulos, I Melakopoulos, D Gika, ... haematologica 91 (7), 968-971, 2006 | 466 | 2006 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 405 | 2020 |
| Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial BJ Monk, A Poveda, I Vergote, F Raspagliesi, K Fujiwara, DS Bae, ... The lancet oncology 15 (8), 799-808, 2014 | 350 | 2014 |
| Renal failure in multiple myeloma: incidence, correlations, and prognostic significance V Eleutherakis-Papaiakovou, A Bamias, D Gika, A Simeonidis, A Pouli, ... Leukemia & lymphoma 48 (2), 337-341, 2007 | 315 | 2007 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 247 | 2017 |
| AURELIA: A randomized phase III trial evaluating bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ... J Clin Oncol 30, 327s, 2012 | 238 | 2012 |
| Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases C Christodoulou, D Bafaloukos, P Kosmidis, E Samantas, A Bamias, ... Annals of Oncology 12 (2), 249-254, 2001 | 226 | 2001 |
| Body mass index and metastatic renal cell carcinoma: clinical and biological correlations L Albiges, AA Hakimi, W Xie, RR McKay, R Simantov, X Lin, JL Lee, ... Journal of Clinical Oncology 34 (30), 3655-3663, 2016 | 220 | 2016 |
| Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of … AM Poveda, F Selle, F Hilpert, A Reuss, A Savarese, I Vergote, ... Journal of Clinical Oncology 33 (32), 3836-3838, 2015 | 220 | 2015 |
| Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study … A Bamias, G Aravantinos, C Deliveliotis, D Bafaloukos, C Kalofonos, ... Journal of Clinical Oncology 22 (2), 220-228, 2004 | 219 | 2004 |
| Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents E Kastritis, A Anagnostopoulos, M Roussou, D Gika, C Matsouka, ... haematologica 92 (4), 546-549, 2007 | 207 | 2007 |
| Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer A Psyrri, M Kassar, Z Yu, A Bamias, PM Weinberger, S Markakis, ... Clinical Cancer Research 11 (24), 8637-8643, 2005 | 200 | 2005 |
